Article

PreciseBreast is prognostic for breast cancer recurrence in a 21-gene assay managed cohort

2025-06-11

Abstract excerpt

<title>Abstract</title> <p>PreciseBreast (PDxBR) is an AI-based digital test that provides individualized risk prediction for invasive breast carcinoma (IBC) independent of a gene expression test and yields important prognostic information that may well guide decision making, especially in patients who do not have access to genomic assays. We aimed to assess the accuracy of risk prediction between 21-gene express...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c025fd6a-cc18-5bd2-95ae-8ca7ac57da39
DOI: 10.21203/rs.3.rs-6529387/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

PreciseBreast is prognostic for breast cancer recurrence in a 21-gene assay managed cohortDOI 10.21203/rs.3.rs-6529387/v1Read

Prospective Validation of a 21-Gene Expression Assay in Breast CancerSemantic proximity Read

Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score.Semantic proximity Read

Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.Semantic proximity Read

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast CancerSemantic proximity Read

Evaluation of an AI-Based Digital Pathology Tool for Breast Cancer Recurrence RiskSemantic proximity Read

Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer RecurrenceSemantic proximity Read

21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.Semantic proximity Read

Comparing an AI test to a 21-gene assay for premenopausal node-positive HR+/HER2-breast cancerSemantic proximity Read

Validation of the predictive ability for recurrence and the clinical utility of the 95-gene classifier (95GC) through an integrated analysis of five studies.Semantic proximity Read

BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization.Semantic proximity Read

Clinical Validation of RlapsRisk BC in an international multi-cohorts settingSemantic proximity Read

Multimodal Prediction of Breast Cancer Recurrence Assays and Risk of RecurrenceSemantic proximity Read